Lung cancer
Conditions
Interventions
Experimental Group:VATS lobectomy with intraoperative phrenic nerve cryoneuroablation
Control Group:Conventional VATS lobectomy
Sponsors
The Affiliated Hospital of Inner Mongolia Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18–75 years old; 2. Gender: No limitation; 3. Confirmed as non-small cell lung cancer (NSCLC) by clinical diagnosis and imaging examinations, with the tumor confined to the lobar region and no distant metastasis; 4. Indication for surgery: According to clinical guidelines, the patient is suitable for thoracoscopic lobectomy + systematic lymph node dissection; 5. FEV1/FVC is within the normal range (generally greater than 70%), or although there is a slight decrease, the residual lung function after surgery is expected to meet the normal respiratory physiological demands. Meanwhile, the diffusing capacity for carbon monoxide (DLCO) should not be lower than 40% of the predicted value; 6. The lesion is primarily located in one or two right lobes, without significant extensive involvement of important structures such as the main bronchus and blood vessels; 7. Good cardiac function and able to tolerate surgery; 8. No severe diseases of the heart, kidneys, liver, or blood system; 9. No history of thoracic surgery; 10. The patient is not undergoing anticoagulant therapy; 11. Patients with normal diaphragmatic movement before surgery; 12. The patient or his/her legal representative has fully understood the content of the study and has signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Age 75 years old; 2. Patients undergoing sublobar resection or pneumonectomy; 3. Patients with complete pleural adhesions who cannot complete the surgery under thoracoscopy, or patients who need to convert to thoracotomy during surgery due to anesthesia, anatomical, or operative factors; 4. Presence of severe diffuse pulmonary disease; 5. Patients undergoing right middle lobe resection; 6. Severe impairment of cardiopulmonary function, unable to tolerate lobectomy; 7. Severe liver or kidney dysfunction; 8. Coagulation dysfunction; 9. Mental and cognitive disorders; 10. Extremely low immune function; 11. Patients who have previously undergone lung surgery; 12. Patients with abnormal diaphragmatic function before surgery; 13. Patients with damage to the phrenic nerve on the affected side or the contralateral side; 14. Patients who have participated in other clinical studies before the start of this study; 15. Postoperative pathology shows non-malignant tumors; 16. Patients who have not signed the informed consent form.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Chest tube indwelling duration;Total drainage volume;Hospital stay duration; | — |
Primary
| Measure | Time frame |
|---|---|
| Incidence of pulmonary air leak;Incidence of prolonged air leak; | — |
Countries
China
Contacts
Public ContactZhanlin Guo
The Affiliated Hospital of Inner Mongolia Medical University
Outcome results
None listed